Related Experiment Video
Updated: Jun 23, 2026
09:07
Electroconvulsive Seizures in Rats and Fractionation of Their Hippocampi to Examine Seizure-induced Changes in Postsynaptic Density Proteins
Published on: August 15, 2017
ACE polymorphism and response to electroconvulsive therapy in major depression
Juhani Akseli Stewart1, Olli Kampman, Martti Huuhka
1University of Tampere, Medical School, 33014 Tampere, Finland. juhani.stewart@uta.fi
Neuroscience Letters
|May 5, 2009
Summary
The angiotensin I-converting enzyme (ACE) gene did not predict electroconvulsive therapy (ECT) response in major depressive disorder (MDD). However, the ACE I/D genotype was linked to earlier depression onset, particularly in males and female heterozygous carriers.
Area of Science:
- Genetics
- Psychiatry
- Molecular Biology
Background:
- The angiotensin I-converting enzyme (ACE) gene is implicated in affective disorders, but findings are inconsistent.
- Understanding ACE gene's role in major depressive disorder (MDD) and treatment response is crucial.
Purpose of the Study:
- To investigate the association between ACE genotype distributions and electroconvulsive therapy (ECT) treatment response in MDD patients.
- To analyze the relationship between ACE genotypes and age of depression onset.
- To compare ACE gene distributions between MDD patients and healthy controls.
Main Methods:
- Genotyping of the ACE gene in 119 treatment-resistant MDD patients and 392 healthy controls.
- Evaluation of MDD patients' treatment response to ECT using the Montgomery-Asberg Depression Scale (MADRS).
- Statistical analysis of genotype distributions, age at onset, and treatment outcomes, with gender-specific analysis.
Main Results:
- No significant association was found between ACE genotype and ECT treatment response in MDD patients.
- A significant association was observed between the ACE I/D genotype and younger age of depression onset in the overall patient group.
- Gender-specific effects were noted: the I allele increased early onset risk in males, while the I/D genotype increased risk in females.
Conclusions:
- The ACE genotype is not a predictor of ECT treatment outcomes in major depressive disorder.
- The ACE genotype, specifically the I/D variant, is associated with an earlier age of onset for depression, with gender-specific nuances.
- ACE gene allele and genotype frequencies did not differ between MDD patients and healthy controls.
More Related Videos
Related Concept Videos
01:30Electroconvulsive Therapy
Electroconvulsive therapy (ECT), or shock therapy, remains a critical biomedical intervention for severe, treatment-resistant depression. While its origins can be traced back to Hippocrates' observations that malaria-induced convulsions alleviated mental illness, modern ECT has evolved significantly from its earlier, more primitive applications. First introduced in 1938 by Ugo Cerletti and his colleagues, ECT involves inducing controlled seizures using electrical currents. In its early years,...
01:23Antidepressant Drugs: MAOIs and Other Agents
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
01:26Psychosis: Goals of Pharmacotherapy
Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation. For...
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
01:30Bipolar Disorder
Bipolar disorder is a chronic mental health condition marked by significant mood fluctuations, including episodes of mania and depression. Elevated energy levels, heightened mood or irritability, impulsive behavior, reduced sleep needs, rapid speech, racing thoughts, inflated self-esteem, and distractibility characterize mania. Individuals with bipolar disorder often alternate between depressive and manic states, with periods of emotional stability lasting an average of six months to a year.